Review of clinical trials and benefit/risk ratio of meloxicam.

  title={Review of clinical trials and benefit/risk ratio of meloxicam.},
  author={A. Barner},
  journal={Scandinavian journal of rheumatology. Supplement},
  • A. Barner
  • Published 1996 in Scandinavian journal of rheumatology. Supplement
Meloxicam is a new once daily non-steroidal anti-inflammatory drug (NSAID). Double-blind trials in over 5000 patients with osteoarthritis and rheumatoid arthritis have shown that meloxicam 7.5 mg and 15 mg are significantly more effective than placebo and comparable in efficacy to standard NSAIDs such as naproxen 750-1000 mg, piroxicam 20 mg and diclofenac 100 mg slow release. In a global safety analysis, both meloxicam doses produced significantly fewer gastrointestinal (GI) side effects than… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…